UEV1A Antibody
Code | Size | Price |
---|
PSI-3375-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3375-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
UEV1A Antibody: CIR1, UEV1, CROC1, UBE2V, UEV-1, UEV1A, CROC-1, P/OKcl.19, Ubiquitin-conjugating enzyme E2 variant 1
Application Note:
UEV1A antibody can be used for detection of UEV1A by Western blot at 1 to 4 μg/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
Background:
UEV1A Antibody: Ubiquitin-conjugating enzyme E2 (UEV1) was initially discovered as a protein similar in sequence and structure to the E2 ubiquitin-conjugating enzymes but lacking their enzymatic activity. There are at least two variants and multiple isoforms of UEV1. In particular, UEV1A (Ubiquitin-conjugating enzyme E2 variant 1 isoform A) has recently been shown to be an important component of the Toll-like receptor and IL-1R signaling pathway. Signals from these pathways are relayed by a number of downstream molecules such as MyD88 and tumor necrosis factor receptor associated factor (TRAF6), ultimately activating various kinases and transcription factors. UEV1A is part of a dimeric ubiquitin-conjugating enzyme complex also containing Ubc13 (ubiquitin-conjugating enzyme 13) that together with TRAF6 activates TAK1, a member of the mitogen-activated protein kinase kinase kinase family. The Ubc13-UEV1A complex also mediates the Lys-63 ubiquitination of TRAF-6, and this ubiquitination is essential for TAK1 activation.
Background References:
- Sancho E, Vila MR, Sanchez-Pulido L, et al. Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells. Mol. Cell Biol. 1998; 18:576-89.
- Akira S and Takeda K. Toll-like receptor Signalling. Nat. Rev. Immunol. 2004; 4:499-511.
- Vogel SN, Fitzgerald KA, and Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 2003; 3:466-77.
- Deng L, Wang C, Spencer E, et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103:351-61.
Buffer:
UEV1A Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%), Chicken: (100%)
Immunogen:
UEV1A antibody was raised against a peptide corresponding to 15 amino acids near the C-terminus of human UEV1A.
The immunogen is located within the last 50 amino acids of UEV1A.
The immunogen is located within the last 50 amino acids of UEV1A.
NCBI Gene ID #:
7335
NCBI Official Name:
ubiquitin-conjugating enzyme E2 variant 1
NCBI Official Symbol:
UBE2V1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_954595
Protein GI Number:
40806167
Purification:
UEV1A Antibody is Ion exchange chromatography purified.
Research Area:
Innate Immunity
SPECIFICITY:
Anti-UEV1A may also recognize other isoforms of UEV1A.
Swissprot #:
Q13404
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | UEV1A Peptide | PSI-3375P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|